IQVIA Holdings Inc. $IQV Position Lifted by SFE Investment Counsel

SFE Investment Counsel grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.1% during the first quarter, HoldingsChannel.com reports. The firm owned 51,922 shares of the medical research company’s stock after purchasing an additional 3,903 shares during the period. IQVIA makes up approximately 1.4% of SFE Investment Counsel’s holdings, making the stock its 19th biggest holding. SFE Investment Counsel’s holdings in IQVIA were worth $8,855,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Boston Partners acquired a new stake in shares of IQVIA during the 3rd quarter valued at approximately $676,698,000. Norges Bank bought a new stake in shares of IQVIA during the 4th quarter valued at about $497,445,000. Victory Capital Management Inc. lifted its holdings in IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after acquiring an additional 1,614,063 shares during the last quarter. Orbis Allan Gray Ltd grew its holdings in shares of IQVIA by 96.5% during the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after purchasing an additional 933,554 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. HSBC reissued a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday. Evercore restated an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Finally, Robert W. Baird raised their target price on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $224.82.

IQVIA Price Performance

IQV stock traded down $0.84 on Friday, hitting $208.13. 747,394 shares of the company’s stock traded hands, compared to its average volume of 1,464,238. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $34.74 billion, a price-to-earnings ratio of 25.79, a P/E/G ratio of 1.78 and a beta of 1.20. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The stock has a fifty day moving average of $181.62 and a 200-day moving average of $188.78.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same period last year, the company posted $2.70 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.